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The	   tumor	  microenvironment	   has	   come	   to	   light	   as	   a	   key	   player	   in	   carcinogenesis	   and	  
progression.	  	  Tumors	  affect	  many	  host	  cell	  types,	  in	  particular	  immune	  cells.	  The	  immune	  system	  
appears	  to	  select	  particularly	  fit	  tumor	  cells	  in	  the	  process	  of	  immuno-­editing,	  while	  the	  tumor	  
cells	   influence	   the	   polarization	   of	   immune	   cells	   towards	   phenotypes	   that	   favor	   tumor	   growth	  
and	  vascularization.	  Here	  we	  investigated	  the	  phenotype	  of	  tumor	  infiltrating	  natural	  killer	  (NK)	  
cells,	   focusing	   on	   angiogenesis	   associated	   cytokines	   and	   activities	   in	   patient-­derived	  material	  
from	  non-­small	  cell	  lung	  cancer	  (NSCLC).	  Samples	  from	  the	  tumor	  and	  adjacent	  normal	  tissues,	  
as	  well	  as	  peripheral	  blood	  and	  lung	  samples	  as	  well	  as	  from	  non-­oncologic	  patients	  with	  bullous	  
emphysema	   were	   collected	   and	   rapidly	   processed	   to	   obtain	   single	   cell	   suspensions.	   Flow	  
cytometry	   (FC)	   analyses	   were	   performed	   to	   evaluate	   specific	   markers	   (CD3,	   CD56,	   CD16)	   to	  
identify	  NK	  cell	  subsets.	  We	  observed	  that	  in	  the	  NSCLC	  samples,	  the	  CD56+CD16-­	  NK	  phenotype,	  
associated	   with	   cytokine	   production,	   predominated	   in	   the	   tumor	   samples	   while	   the	  
CD56dimCD16+	  cytotoxic	  phenotype	  dominated	  in	  the	  adjacent	  normal	  tissues	  and	  in	  lung	  tissue	  
derived	   from	   non-­oncologic	   patients.	   This	   was	   independent	   of	   tumor	   histotype	   and	   smoking	  
status.	   We	   examined	   the	   angiogenic	   potential	   of	   tumor	   infiltrating	   NK	   cells	   by	   intracellular	  
staining	   for	  production	  of	  VEGF,	  PlGF,	   IL-­8	  (CXCL8),	   IFNγ	  and	  other	  markers.	  The	  CD56+CD16-­	  
subset	  was	  clearly	  associated	  with	  production	  of	  angiogenic	  cytokines	  in	  all	  samples.	  However,	  
patients	   with	   squamous	   carcinoma	   histotypes	   showed	   remarkably	   and	   significantly	   higher	  
production	   of	   angiogenic	   factors	   in	   tumor	   infiltrating,	   adjacent	   tissue	   and	   especially	   in	  
peripheral	  blood	  CD56+CD16-­	  NK	  cells	  than	  patients	  with	  adenocarcinomas.	  Following	  surgical	  
intervention,	  these	  levels	  were	  reduced	  in	  disease-­free	  patients.	  Moreover,	  supernatants	  derived	  
from	  the	  tumor	  infiltrating	  CD56+CD16-­	  NK	  cells	  were	  able	  to	  induce	  endothelial	  cell	  chemotaxis	  
and	   formation	   of	   capillary-­like	   structures	   in	   vitro;	   this	   was	   particularly	   evident	   for	   NK	   cells	  
isolated	  from	  squamous	  cell	  carcinomas.	  Our	  data	  suggest	  that	  squamous	  NSCLC	  tumors	  have	  a	  
significant	   systemic	  effect	  on	  NK	  cells,	   enhancing	  angiogenic	   cytokine	  production	   in	  a	  manner	  
dependent	  on	  the	  presence	  of	  disease.	  NK	  cells	  appear	  to	  participate	  in	  tumor	  neovascularization	  
and	  could	  represent	  a	  peripheral	  marker	  for	  disease	  progression,	  angiogenesis	  and	  response	  to	  
therapies	  in	  some	  tumor	  subsets.	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1.  INTRODUCTION 
 
1. 1  Angiogenesis and tumor angiogenesis 
 
Angiogenesis, the formation of new blood vessels, is a crucial process in a number of physiological 
events, including reproduction, development, tissue repair and wound healing. The angiogenesis 
process depends on a balance between angiogenic promotors and inhibitors. An excess of 
angiogenic factors over angiogenesis inhibitors, determines a break of this equilibrium and the 
onset of “angiogenic diseases”, including cancer.  
Angiogenesis is characterized by phases involving diverse factors and cell types as well as their  
interactions. These phases include: 
 
• Production of angiogenic factors – often due to hypoxia 
• Release of factors and their interaction with their specific receptors on the surface of 
endothelial cells  
• Endothelial cell activation and  proliferation 
• Directional migration of endothelial cells 
• Degradation of the extracellular matrix (ECM) (by enzymes) and ECM remodelling 
• Morphogenic reorganization into a network, the formation of lumens making capillary tubes 
• Recruitment of supporting cells: pericites, smooth muscle cells, and elaboration of the 
basement membrane 
• Vascular stabilization 
 
Experimental studies have shown that tumors without a vasculature are limited to only a few mm3 
in dimension; most tumors require the capacity of inducing the formation of a new blood supply to 
overcome the physical limitations on the diffusion of nutrients and oxygen within the tumor 
(Ferrara N. and Kerbel RS, 2005; Folkman J, 2006; Hanahan D and Folkman J, 1996; Hanahan D 
and Weinberg RA, 2000; Kerbel R and Folkman J, 2002), a critical step in progression known as 
the “angiogenic switch” (Hanahan	  D	  et	  al.,1996). 
Tumor blood vessels are characterized  by  profound differences in structure and organization 
respect  to normal vessels. Tumor vessels are tortuous, leaky and poorly functional, they display 
altered expression of surface antigens, have few pericites. Tumor cells are able to produce 
numerous angiogenic factors including cytokines, chemokines, growth factors, cell adhesion 
molecules, extracellular matrix components, proteolytic enzymes. Angiogenesis-associated factors 
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include the vascular endothelial growth factors (VEGFs), the fibroblast growth factors (FGFs), 
hepatocyte growth factor (HGF), epidermal growth factor (EGFs), interleukin-8 (IL-8), placental 
growth factor (PlGF), platelet derived growth factor (PDGF), insulin like growth factor (IGF-I), 
transforming growth factor (TGF-α, TGF-β), tumor necrosis factor (TNF-α), macrophage colony 
stimulating factor (M-CSF), Angiopoietins, Angiogenin. 
Recent studies on the tumor microenvironment suggest that it is an integral and essential part of 
cancer  (Noonan DM et al., 2008;  Albini A et al., 2007; de Visser KE et al., 2006).  
The tumour microenvironment is a complex society of many cell types, including endothelial cells 
(ECs) and their precursors, pericytes, smooth-muscle cells, fibroblasts of various phenotype, 
myofibroblasts, neutrophils, eosinophils, basophils, mast cells, lymphocytes (T, B, NK cells) and 
antigen-presenting cells (APCs) such as macrophages and dendritic cells. All these cells have a 
crucial role in tumor progression, stimulating the formation of the blood vessels (Albini A, Sporn 
MB, 2007). All these factors and cells producing them are potential targets of new therapeutic 
strategies against the so called “angiogenic diseases” 
 
1. 2  Role of  innate immunity in tumor angiogenesis 
 
1. 2. 1  Monocytes/macrophages and Tumor Associated Macrophages (TAM) 
 
Macrophage heterogeneity reflects the plasticity of these cells in response to microenvironmental 
signals, such as cytokines and microbial products, which in turn produces diverse functional 
programs and influences polarization of the immune system.  Macrophages have a key role in 
promoting the orientation of the adaptive immune response typically towards either a Th1 or Th2 
response, as well as by expressing specialized and polarized effector functions themselves (Goerdt 
S and Orfanos CE, 1999; Gordon S, 2003; Mantovani A et al., 2002; Sica A and Bronte V, 2007).  
Numerous data indicate that macrophages can be phenotypically polarized by the microenvironment 
to mount specific functional programs: either the classical (or M1) activation of effector cells able 
to kill tumor cells, or the alternative activation (M2) closely related to the tumor-associated 
macrophage (TAM) profile. M1 macrophages are generally characterized by an IL–12high, IL-23high, 
IL-10low phenotype, with obvious consequences in driving a Th1 response and can also produce 
copious amounts of reactive oxygen and nitrogen intermediates (Goerdt S and Orfanos CE, 1999; 
Gordon S, 2003; Mantovani A et al., 2002; Sica A and Bronte V, 2007).  The M1 macrophages, a 
terminology mirroring the Th1 nomenclature, are part of the afferent and efferent limbs of Th1 
responses and help mediating resistance against intracellular parasites and tumors.  On the other 
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extreme we have alternatively activated (M2) macrophages induced by cytokines such as IL-4 and 
IL-13, which share an IL-12low, IL-23low, IL-10high phenotype. These M2-polarized leukocytes are 
generally oriented to tissue remodeling and repair, immunosuppression and angiogenesis 
(Mantovani A et al., 2008) and substantial data show that an M2 polarized inflammation is a key 
feature of the tumor microenvironment (Mantovani A et al., 2002; Sica A and Bronte V, 2007) 
influencing angiogenesis, invasion and metastasis, as well as subversion of adaptive immunity.  
The diverse polarized macrophages differ in terms of receptor expression, cytokine production 
profiles, chemokine repertoires and effector function. Induction of an M2 phenotype appears to be 
due to STAT3 activation and/or inhibition of STAT1 phosphorylation (Hu X et al., 2003; Ito S et 
al., 1999; Mantovani A et al., 2002; Riley JK et al., 1999), down-regulation of p65 containing NF-
κB and generation of p50 NF-κB homodimers (Porta C et al., 2009).  NF-κB is a key axis in tumor 
angiogenesis, induction of the angiogenic program in ECs involves NF-κB activation (Karin M, 
2006), and numerous angiogenesis inhibitors repress NF-κB (Albini A, Noonan DM and Ferrari N, 
2007).  In addition, chemotherapy and radiotherapy widely used in treatment of cancer patients also 
induces NF-κB both in normal and cancer cells (Nakanishi C and Toi M, 2005), resulting in 
induction of inflammation, angiogenesis and tumor reconstruction. Tumor inflammation was 
historically considered to be part of an abortive rejection process, now the role of tumor associated 
macrophages (TAMs), has undergone extensive re-evaluation, expressing properties that facilitate 
tumor growth and progression by stimulating tumor-cell proliferation, angiogenesis and favoring 
invasion and metastasis (Balkwill F and Mantovani A, 2001; Lewis C and Murdoch C, 2005; 
Mantovani A et al., 2002; Pollard JW, 2004).  TAMs derived from circulating monocytic precursors 
are directed into the tumor by chemokines, largely through hypoxia-dependent mechanisms 
involving VEGF and the CXCL12/CXCR4 axis (Mantovani A et al., 2002; Saccani A et al., 2006; 
Schioppa T et al., 2003).  Analyses of TAMs indicate that these express an M2-associated 
phenotype, with a similar transcriptome profile oriented toward tissue remodeling and repair, 
immuno-suppression and angiogenesis (Biswas SK et al., 2006; Mantovani A et al., 2002; Murdoch 
C et al., 2008).  
TAMs recruited into tumors are primarily attracted and/or immobilized into avascular (Leek RD et 
al., 1996) and necrotic (Leek RD et al., 1999) areas of hypoxia, (O'Sullivan C and Lewis CE, 1994; 
Harmey JH et al., 1998). Recent in vitro data show that TAMs are stimulated by hypoxia in such 
sites to co-operate with tumor cells to promote revascularization (Murdoch C et al., 2008; Schioppa 
T et al., 2003) in fact the level of hypoxia present in these areas stimulates the release of VEGF 
from human macrophages (Lewis JS et al., 1999) through up-regulation of transcriptional factors 
including hypoxia inducible factors (HIFs 1 and 2) that activate genes leading to the release of 
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glycolytic, proangiogenic and proinvasive molecules. (Leek RD et al., 2000), such as TNFa (Pusztai 
L et al., 1994), IL-8 (Fujimoto J et al., 2000), and CXCL12 (Schioppa T et al., 2003), matrix 
metalloproteinases (MMPs 1, 2, 3, 9, and 12) (Deryugina EI and Quigley JP, 2009; Egeblad M and 
Werb Z, 2002), plasmin, urokinase plasminogen activator and its receptor (Pyke C et al., 1993). The 
proteolytic activity exerted contributes to the migration and proliferation of ECs and also to the 
migration and extravasation of tumor cells during the metastatic process (Deryugina EI and Quigley 
JP, 2009; Egeblad M and Werb Z, 2002). A series of studies have found that hypoxia itself 
promotes the invasive program that favors metastatic dissemination, and that VEGF based 
angiogenesis inhibition can result in a greater incidence in metastasis (Ebos JM et al,2009; Paez-
Ribes M et al., 2009). A TAM subset that appears to have a particularly intriguing role in 
angiogenesis is the one of Tie2 expressing macrophages or TEMs (De Palma M et al., 2007; De 
Palma M and Naldini L, 2009), closely associated with the forming vasculature but that do not 
appear to incorporate into it as other precursors do.  Specific deletion of this TAM subset results in 
inhibition of angiogenesis and repression of tumor growth, indicating that TEMs are key targets for 
anti-angiogenic therapy (De Palma M et al., 2007; De Palma M and Naldini L, 2009; Pulaski HL et 
al., 2009). Further, these cells can also be used as “Trojan horses” to vehicle anti-angiogenic and 
anti-tumor therapies into the tumor (De Palma M and Naldini L, 2009).   
 
1. 2. 2  Myeloid derived Suppressor Cells (MDSC) 
 
Myeloid derived suppressor cells (MDSCs) represent a range of poorly differentiated myeloid 
precursor that shares markers for both monocyte and granulocytes (Serafini P, Borrello I and Bronte 
V, 2006). These cells, originally identified in murine models are characterized by potent immuno-
suppressive activity expressed through a variety of mechanisms, including production of TGFb, 
high level of inducible nitric oxide synthase (NOS2) and arginase (Arg1), which deplete arginine 
within the tumor microenvironment, as well as mechanims that deplete cystine and cysteine 
(Srivastava MK et al., 2010), all of which contribute to T cell suppression and apoptosis (Bronte V 
and Zanovello P, 2005; Kusmartsev S and Gabrilovich DI, 2006; Bronte V, 2009; De Santo C et al., 
2005; Dolcetti L et al., 2010).  MDSCs are also powerful promoters of angiogenesis by MMP 
(Yang L et al., 2004) and VEGF production (Sica A and Bronte V, 2007) subsequent to Stat3 
activation (Kujawski M et al., 2008). MDSC tumor infiltrates have been reported to be responsible 
for the resistance of tumors to anti-angiogenic therapy (Shojaei F et al., 2007) (Shojaei F et al., 
2009), largely via production of diverse angiogenic factors such as Bv8 (Shojaei F et al., 2007, 
Shojaei F and Ferrara N, 2008).  
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Myeloid precursors have also been found to be elevated in human cancers (Almand B et al., 2001; 
Diaz-Montero CM et al., 2009; Ostrand-Rosenberg S and Sinha P, 2009; Rodriguez PC et al., 2009) 
and to correlate with disease status (Diaz-Montero CM et al., 2009) where a variety of myeloid 
cells, blocked at different stages of maturation along the monocytic or granulocytic pathways, are 
present (Ostrand-Rosenberg S and Sinha P, 2009). The role of human MDSCs in tumor 
angiogenesis is not fully understood and the main question is how to target these cells: approaches 
were largely directed towards immune-suppressive activity including use of nitric oxide donors, 
such as Nitroaspirin (De Santo C et al., 2005; Ugel S et al., 2009), that interfer with recruitment and 
subsequent angiogenesis by blocking the CSF-1 receptor (Priceman SJ et al., 2009) 
 
1. 2. 3  Neutrophils 
 
Neutrophils are the most abundant circulating leukocyte in humans and the primary granulocytes 
involved in angiogenesis.  These cells play a primary role in responses to diverse infective agents, 
based mostly on pattern recognition mechanisms.  They are quickly and massively recruited into 
areas producing danger signals and store in granules several soluble mediators that can be rapidly 
secreted in both physiological and pathological conditions as well as respiratory burst production of 
reactive oxygen species (O2-, H2O2, HOCl).  These factors can produce tissue destruction and lysis, 
resulting in significant anti-tumor activity (Di Carlo E et al., 2001).  Neutrophils are also sources for 
several cytokines (including TNFα, IL-1β, IL-1Rα, IL-12 and VEGF), and chemokines (including 
CXCL1, CXCL-8, CXCL9, CXCL10, CCL3, and CCL4) (Scapini P et al., 2000). These products 
can influence the immune response and polarization as well as promote tissue reconstruction and 
angiogenesis. Neutrophils are able to produce a broad range of angiogenic factors (Schruefer R et 
al., 2005; Schruefer R et al., 2006), we noted that neutrophils appeared to lead the invasion of 
vessel sprouts into a matrigel sponge containing tat (Benelli R et al., 2000). The use of corneal 
pocket assays indicated that angiogenesis induced by IL-8 (CXCL8), a chemokine highly active on 
neutrophils and a known angiogenic factor, acted through CXCR2 receptors expressed on ECs 
(Addison CL et al., 2000).  However, not all endothelial cells express CXCR2 and subsequent 
studies demonstrated that neutrophils were required for the angiogenic response to IL-8 stimulation 
(Benelli R et al., 2002).  The link between IL-8 production and subsequent tumor-associated 
neutrophil (TAN) recruitment has been confirmed in tumor models, where this cascade was shown 
to be critical in linking ras oncogene expression to tumor growth and angiogenesis (Sparmann A 
and Bar-Sagi D, 2004). TANs have also been shown to be a key source of Metallo-Matrix-
Proteinase 9 (MMP9), a protease required for the angiogenic switch and tumor growth in skin 
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carcinogenesis and in Rip-Tag pancreatic cancer models (Coussens LM et al., 2000; Nozawa H, 
Chiu C and Hanahan D, 2006).  The inflammation-associated angiogenic response during wound 
healing was significantly delayed in animals harboring genetic defects that compromise neutrophil 
recruitment, in particular deletion of CXCR2 (Devalaraja RM et al., 2000) or CD18 (Schruefer R et 
al., 2006). Similarly, a dual src kinase knock-out that compromised neutrophil function also blocked 
the ability to induce angiogenesis in response to CXCL1 (Scapini P et al., 2004).  In this case the 
neutrophils were recruited into the site, but were unable to release VEGF, a factor critical for 
induction of the angiogenic response. Intriguingly, in a major site of physiological angiogenesis in 
adults, the endometrium, neutrophils closely associate with the growing vessels and appear to be the 
primary source of VEGF for these vessels (Gargett CE et al., 2001; Heryanto B, Girling JE and 
Rogers PA, 2004; Lin YJ et al., 2006; Na YJ et al., 2006), thus intimately nurture angiogenesis in 
this organ.  
The divergent roles for neutrophils, on one hand able to produce anti-tumor tissue 
destruction, on the other to supply angiogenic factors and tissue regeneration signals, and the 
reports of multiple neutrophil subsets(Tsuda Y et al., 2004) lead to the speculation that several 
subsets of neutrophils may exist, in particular pro- and anti-angiogenic subsets (Noonan DM et al., 
2008). This hypothesis is supported also by the role that neutrophils recruitment seem to have in 
PPARa knock-out mouse models (Kaipainen A et al., 2007). In fact tumors injected into PPARa 
knock-out mice remained in an essentially dormant state, with notable neutrophil recruitment and 
production of the anti-angiogenic matrix molecule thrombospondin while neutrophil depletion 
permitted angiogenesis and tumor growth, indicating an anti-tumor phenotype dictated by the loss 
of PPARa (Kaipainen A et al., 2007). In the other hand instead, in wild-type mice, neutrophil 
depletion slowed tumor growth consistent with a pro-angiogenic activity (Nozawa H, Chiu C and 
Hanahan D, 2006; Pekarek LA et al., 1995). Additional support for the existence of multiple 
neutrophil subsets with either pro- or anti-tumor activity comes from analyses of the effects of 
TGFb blockades. TGFb is an immunosupressive cytokine that itself has a dichotomous activity in 
cancer: inhibitory at early stages and enhancer of tumor progression and immunosuppression at 
later stages when is frequently found in the tumor microenvironment (Bierie B and Moses HL, 
2006).  Blockage of TGFb in diverse tumor models can lead to enhanced CD8+ T cell activity and 
to accumulation of tumor associated neutrophils (TAN) within the tumor lead to mass regression in 
human and mice (Ge R et al., 2006; Nam JS et al., 2008; Suzuki E et al., 2007; Fridlender ZG et al., 
2009) while on the contrary depletion of neutrophils under TGFb blockade impaired CD8+ T cell 
activation and enhanced tumor growth. Even in this case the authors lean towards the idea of the 
existence of two different neutrophil subsets: pro-tumoral neutrophils, termed “N2” in concordance 
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with the M2/Th2 paradigm, linked to the presence of TGFb, and anti-tumoral neutrophils, “N1”, 
recruited into tumors when TGFb turn to be inactive. These findings were similar in two different 
tumor types (NSCLC and mesothelioma) and in three different mice strains, suggesting that the 
polarization of neutrophils may be a general feature of tumor microenvironment (Fridlender ZG et 
al., 2009). However the potential role in angiogenesis of these cells was not fully investigated yet  
 
1. 2. 4  Mast cells 
 
Mast cells were initially suggested to be involved in vascularization during rheumatoid arthritis 
(Maruotti N et al., 2007; Ribatti D, Contino R and Tursi A, 1988), and appear to play a key role in 
angiogenesis in allergic reactions as well (Crivellato E, Travan L and Ribatti D, 2009).  These cells 
are intimately involved in vascularization of hematologic malignancies, (Ribatti D, Crivellato E and 
Molica S, 2009), where they appear to integrate into the vessel wall through the process of  vascular 
mimicry (Nico B et al., 2008) while play a significant role in solid tumor angiogenesis (Crivellato 
E, Nico B and Ribatti D, 2008; Murdoch C et al., 2008; Ribatti D et al., 2001).  In fact, mast cells 
contribute to the angiogenic switch producing numerous angiogenesis-associated cytokines and 
chemokines (Murdoch C et al., 2008; Ribatti D et al., 2004) and proteases that promote 
premalignant angiogenesis (Coussens LM et al., 1999; Ranieri G et al., 2009; Soucek L et al., 
2007). Therefore mast cells are considered a new target for anti-angiogenic therapies (Galinsky DS 
and Nechushtan H, 2008; Liu J et al., 2009). 
 
1. 2. 5  Dendritic Cells (DCs) 
 
Dendritic cells (DCs) constitute a heterogeneous population of antigen presenting cells found in 
virtually every tissue, which through their antigen presentation and cytokine secretion activities 
contitute the link between innate and adaptive immunity (Lanzavecchia A and Sallusto F, 2001; 
Steinman RM and Banchereau J, 2007). Although their clinical relevance is a matter of debate DCs 
recruitment into tumors have been documented in several studies (Balkwill F, 2004; Sozzani S, 
Allavena P and Mantovani A, 2001; Ueno H et al., 2007; Vicari AP, Treilleux I and Lebecque S, 
2004),. Within the tumor microenvironment, DCs generally show an immature phenotype 
characterized by the low expression of co-stimulatory molecule and IL-12 production (Vermi W et 
al., 2003; Vicari AP, Treilleux I and Lebecque S, 2004), apparently due to cytokines that block 
differentiation and maturation (IL-10, IL-6, TGFb, VEGF and M-CSF) (Ratta M et al., 2002; 
Steinman RM and Banchereau J, 2007). Tumor associated DCs maintain tolerance to tumor 
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antigens, promote angiogenesis, tumor growth, progression and dissemination (Mantovani A et al., 
2002;Sozzani S et al., 2007). DCs express a wide array of pro- and anti-angiogenic mediators that 
might have a significant role in those pathophysiological settings characterized by DC activation 
and angiogenesis, including inflammation, wound healing, atherosclerosis and tumor growth 
(Sozzani S et al., 2007). These mediators, members of distinct families, modulate 
neovascularization by different mechanisms of action (Mantovani A, 2004; Sozzani S, 2005). 
DCs release classical angiogenic growth factors that act on the endothelium by engaging the 
corresponding signaling receptors on cell surface. Conventional DCs express VEGF-A, FGF2 and 
ET-1 (Guruli G et al., 2004; Riboldi E et al., 2005; Bourbie-Vaudaine S et al., 2006; Piqueras B et 
al., 2006). On the other hand these cell subset can release cytokines that repress angiogenesis such 
as IL-12 (Albini A et al., 2009; Noonan DM et al., 2008; Trinchieri G, 2003), IFNg (Trinchieri G, 
2003) and the angiostatic chemokines CXCL9, CXCL10 and CCL21 (Piqueras B et al., 2006). DCs 
can release cytokines, which although devoid of a direct pro-angiogenic activity, can  increase EC 
responsiveness to classic angiogenic growth factors (such as TNFa (Caux C et al., 1994; de Graaf 
JH et al., 1996; Verhasselt V et al., 1997), Osteopontin (OPN) (Konno S et al., 2006; Naldini A et 
al., 2006), IL-6, TGFb, (Verhasselt V et al., 1997), CXCL1/2/3/5/8 and CCL2 (Means TK et al., 
2003; Scimone ML et al., 2005; Vermi W et al., 2006;Curiel TJ et al., 2004; Penna G et al., 2002; 
Piqueras B et al., 2006) or up-regulate the production of angiogenic factors by other cell types. DCs	  
can	  produce	  anti-­‐angiogenic	  ECM	  components	  including	  thrombospondin-­‐1	  (TSP-­‐1)	  (Doyen	  V	  
et	  al.,	  2003;	  Rusnati	  M	  and	  Presta	  M,	  2006)	  and	  long-­‐pentraxin-­‐3	  (PTX3)	  (Doni	  A	  et	  al.,	  2006;	  
Doni	   A	   et	   al.,	   2003;	   Garlanda	   C	   et	   al.,	   2005)	   or	   can	   transdifferentiate	   into	   endothelial	   cells	  
(Coukos	  G	   et	   al.,	   2005),	   similarly	   to	   that	   reported	   for	   hematopoietic	   precursors,	   circulating	  
endothelial	  precursors	  (CEPs)	  and	  circulating	  endothelial	  cells	  (CECs)	  (Dome	  B	  et	  al.,	  2009).	  	  
	  
1. 2. 6  Natural Killer Cells (NKs) 
 
NK cells are classified as the third kind of cells differentiated from the common lymphoid 
progenitor generating also B and T lymphocytes (Di Santo JP, 2008). They were originally 
described as large granular lymphocytes active against tumor cells and endowed with both cytotoxic 
and cytokine-producing functions. NKs serve to contain viral infections while the adaptive immune 
response is generating antigen-specific cytotoxic T cells that can clear the infection (Vivier E et al., 
2004). The acquisition of cytotoxic capabilities during evolution has been associated with the 
development of highly sophisticated and robust mechanisms controlling the cytolytic processes in 
order to avoid tissue damage. In fact the NK cell activation system operates through a variety of cell 
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surface receptors that activate or repress NK cell functions (Chiesa S et al., 2005; Vivier E et al., 
2004). Thus, the integration of antagonistic pathways upon interaction with neighboring cells 
governs the dynamic equilibrium regulating NK cell activation dictates whether or not NK cells are 
enrolled to kill target cells in response to interferons or macrophage-derived cytokines (Eissman P 
et al., 2010).  
To control their cytotoxic activity, NK cells possess two types of surface receptors: activating 
receptors (KARs) and inhibitory receptors (KIRs) (Chiesa S et al., 2005; Vivier E et al., 2004). Most 
of these receptors are not unique to NK cells and can be present in some T cell subsets as well.   
Activating NK cell receptors detect the presence of ligands on cells in ‘distress’, such as the stress-
induced self ligands recognized by NKG2D (ULBP and MIC in human and RAE1, H60 and 
MULT1 in mouse) or other alert molecules including infectious non-self ligands (for example, the 
cytomegalovirus-encoded m157 recognized by Ly49H in the mouse) and Toll-like receptor (TLR) 
ligands. Indeed, NK cells express several TLRs and in vitro exposure of NK cells to TLR ligands 
induces IFN production and enhances cytotoxicity. However, this process is more efficient when 
accessory cells are present together with NK cells, suggesting that the role of TLRs in NK cells in 
vivo might be not direct (Gerosa et al, 2005, Hart OM et al, 2005). NK cells also express the low-
affinity Fc receptor CD16, that enable them to detect antibody-coated target cells to exert antibody-
dependent cell cytotoxicity (ADCC). 
NK cells appear to determine whether a cell is infected or not through recognition of an "altered 
self" state in particular involving the expression levels of Major histocompatibility complex (MHC) 
class I molecules on the target cell surface, the main mechanism by which cells display viral or 
tumor antigens to cytotoxic T cells (Chiesa S et al., 2005; Vivier E et al., 2004. A common 
evolutionary adaption to this, seen in both intracellular microbes and tumours, is a chronic down-
regulation of these MHC I molecules, rendering the cell resistant to T cell mediated immunity. It is 
believed that NK cells, in turn, evolved in response to this adaption, since NKs use their inhibitory 
receptors to evaluate the absence of MHC class I molecules on susceptible target cells (Yokoyama, 
W.M et al, 2005, Hart, O.M., Athie-Morales et al, 2005). Inhibition of NK cell activity by MHC 
class I molecules is crucial to the role played by NK cells. The MHC class I–specific inhibitory 
receptors include the killer cell immunoglobulin-like receptors (KIRs) in human, the lectin-like 
Ly49 dimers in mouse and the lectin-like CD94-NKG2A heterodimers in both species (Yokoyama, 
W.M et al, 2005, Hart, O.M., Athie-Morales et al, 2005) that share conserved intracytoplasmic 
inhibitory signaling domains called immunoreceptor tyrosine-based inhibition motifs (ITIMs). By 
interacting with MHC class I molecules, constitutively expressed by healthy cells, inhibitory 
receptors provide a way for NK cells to ensure tolerance to self while allowing toxicity toward 
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stressed cells that can down-regolate the expression of the MHC class I molecules. MHC class I is 
not the only constitutive self signal detected by NK cells as other inhibitory receptors, for example 
NKR-P1B and 2B4 in mouse and NKR-P1A in human, recognize non-MHC self molecules (Clr-b, 
CD48 and LLT-1 respectively) and regulate NK cell activation. 
Consistent with their function as innate sentinels, NK cells are widespread throughout lymphoid 
and nonlymphoid tissues where they represent a minor fraction of total lymphocytes (from 2% to 
10% in mouse’s organs and from 2% to 18% in human peripheral blood (Parham, P. et al, 2005), 
also distinct NK cell subsets have been defined in mice and humans based on phenotypic, 
functional and anatomical features (Chiossone L er al., 2007). 
In humans, the CD56dimCD16+ NK cell subset constitutes about 90-95% of peripheral blood NKs.  
These cells  readily kill target cells upon proper recognition and secrete low cytokine levels (Cooper 
MA, Fehniger TA and Caligiuri MA, 2001). In contrast, CD56brightCD16- NK cells (about 5-10% of 
peripheral blood NKs) are poorly cytotoxic but produce large amounts of cytokines, including 
IFNg, TNFa, and GM-CSF. Only CD56bright NK cells express secondary lymphoid organ homing 
markers such as CCR7, CD62L and CXCR3, resulting in an enrichment of this subset in lymphoid 
organs and sites of inflammation (Campbell J et al., 2001; Fehniger TA et al., 2003; Ferlazzo G et 
al., 2004b).  
The question of whether or not the development of the human subsets is interconnected has been 
under investigation for some time. Recently, a number of studies suggested that CD56brightCD16- 
NK cells are able to differentiate into CD56dimCD16+ NK cells upon prolonged activation (Chan A 
et al., 2007; Romagnani C et al., 2007), while the reverse may be possible in the presence of TGFβ 
(Keskin DB et al., 2007).  
TGFβ has been reported to be able in polarizing CD56+CD16+ subset into CD56dimCD16- during 
development  and differenziation (Allan DS et al., 2010); TGFb is also present in tumor 
microenvironment (Noonan DM et al., 2008; Serrati S et al., 2008) and its capacity in swincing on 
CD56+CD16+ subset into CD56dimCD16 has been already reported (Keskin DB et al., 2007), 
displaing phenotypic similarityes with CD56brightCD16- decidual NKs (dNKs) that have been shown 
to  produce hight level of pro-angiogenic factors.  
 NK subset distribution differs between distinct anatomical sites, for example in secondary 
lymphoid organs, lung, liver, and skin, suggesting specialization (Ferlazzo G and Munz C, 2004; 
Ferlazzo G et al., 2004; Gregoire C et al., 2007; Trinchieri G, 1989). A particular 
CD56superbrightCD16- NK cell subset (dNKs) is found in the deciduas during implanatation (Hanna J 
et al., 2006; Hanna J and Mandelboim O, 2007;Kopcow HD et al., 2005). The dNKs have low 
cytotoxicity and guide decidual angiogenesis by producing high levels of angiogenic factors, in 
	   15	  
particular VEGF and PlGF (Hanna J et al., 2006) and promote decidual cellularity (Ashkar AA, Di 
Santo JP and Croy BA, 2000). The CD56brightCD16- NK cell subset is recruited into tumors 
(Carrega P et al., 2008) and although NK cells infiltration appears to correlate with a better 
prognosis in gastric (Ishigami S et al., 2000), colorectal (Coca S et al., 1997), and lung carcinomas 
(Takeo S et al., 1986; Villegas FR et al., 2002) we have speculated that tumor infiltrating NK cells 
may be switched to an angiogenic cytokines producing phenotype similar to dNK cells (Noonan 
DM et al., 2008). 
 
1. 3  Non Small Cell Lung Cancer (NSCLC) 
	  
Lung cancer is currently one of the most common malignancies and NSCLC represents about 
75-80% af oll cases of lung cancers (Carrega P et al., 2008). The most common types of NSCLC 
are adenocarcinoma, squamous cell carcinoma (Carega P et al., 2008), and large cell carcinoma, but 
there are several other types that occur less frequently, and all types can occur in unusual histologic 
variants. Several risk factors contribute to the development of lung cancer. The risk factors include 
the following: Tobacco use (cigarette, pipe, or cigar smoking) and exposure to second-hand smoke; 
chemical or physical agents: radon, arsenic, asbestos, chromates, chloromethyl ethers, nickel, 
polycyclic aromatic hydrocarbons, radiation (often for therapy) to the breast or chest. 
Although NSCLCs are associated with cigarette smoke, adenocarcinomas may be found in 
patients who have never smoked. The single most important risk factor for the development of lung 
cancer is smoking. For smokers, the risk for lung cancer is on average tenfold higher than in 
lifetime nonsmokers (defined as a person who has smoked <100 cigarettes in his or her lifetime). 
The risk increases with the quantity of cigarettes, duration of smoking, and earlier starting age. 
Smoking cessation results in a decrease in precancerous lesions and a reduction in the risk of 
developing lung cancer. Former smokers continue to have an elevated risk for lung cancer for years 
after quitting. Squamous cell carcinomas are linked more strongly with smoking than other forms of 
NSCLC. The incidence of squamous cell carcinoma of the lung has been decreasing in recent years, 
such that adenocarcinoma is now the most common histologic subtype in many countries. This is 
likely due to changes in cigarette manufacture and smoking habits.	    Currently in most western 
countries, adenocarcinomas represent about 40% of NSCLC, followed by squamous cell carcinoma 
(25%), large cell carcinoma (10%), and the remainder several other subtypes with lower frequency. 
As a class, NSCLCs are relatively insensitive to chemotherapy and radiation therapy 
compared with SCLC. Patients with resectable disease may be cured by surgery or surgery followed 
by chemotherapy. Local control can be achieved with radiation therapy in a large number of 
	   16	  
patients with unresectable disease, but complete remission is seen only in a small number of 
patients. Patients with locally advanced unresectable disease may achieve long-term survival with 
radiation therapy combined with chemotherapy. Patients with advanced metastatic disease may 
achieve improved survival and palliation of symptoms with chemotherapy, targeted agents, and 
other supportive measures. 
NSCLC arises from the epithelial cells of the lung of the central bronchi to terminal alveoli. 
The histological type of NSCLC correlates with site of origin, reflecting the variation in respiratory 
tract epithelium of the bronchi to alveoli. Squamous cell carcinoma usually starts near a central 
bronchus. Adenocarcinoma and bronchioloalveolar carcinoma usually originate in peripheral lung 
tissue. Although NSCLCs represent a heterogeneous aggregate of histologies, approaches to 
diagnosis, staging, prognosis, and treatment are similar. 
In NSCLC, the determination of stage is important in terms of therapeutic and prognostic 
implications. Careful initial diagnostic evaluation to define the location and to determine the extent 
of primary and metastatic tumor involvement is critical for the appropriate care of patients. Stage	  
has a critical role in the selection of therapy. The stage of disease is based on a combination of 
clinical factors and pathological factors (Pfister D.G. et al., 2004). In NSCLC, results of standard 
treatment are poor except for the most localized cancers. Surgery is the most potentially curative 
therapeutic option for this disease. Postoperative chemotherapy may provide an additional benefit to 
patients with resected NSCLC. Radiation therapy combined with chemotherapy can produce a cure 
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2.  AIMS AND RATIONAL OF THE STUDY 
	  
 
In addition to excessively proliferating neoplastic cells, tumors are tissues that contain host 
components including stromal cells, a vasculature and a characteristic inflammatory infiltrate 
associated with the constant remodeling that tumors undergo. It is increasing recognized that these 
host cells also represent key therapeutic targets, and clinical data have now demonstrated that 
inhibition of tumor vascularization with specific agents significantly prolongs patient survival. 
However, the clinical benefit obtained with anti-angiogenic agents is as yet still in terms of months 
but there is vast room for improvement. Myeloid cell infiltrates have been found to be responsible 
for the resistance of tumors to anti-angiogenic therapy, largely via production of diverse angiogenic 
factors such as Bv8, thus it is clear that these cells represent a therapeutic target. Among the 
mechanisms of immune system tumor promotion, there is rapidly expanding evidence that the 
innate immune system plays a key role in orchestrating angiogenesis in cancer as well as other 
pathological and physiological conditions. 
IL-12 is a potent Th1 cytokien that is also endowed with significant anti-angiogenic activity.  
This cytokine plays a key role in angiogenesis inhibiton by at least some endogenous angiogenesis 
inhibitors such as angiostatin (Morini M et al., 2004).  Previous studies using blocking antibodies 
and bolus protein treatments indicated that the anti-angiogenic activity depended on induction of 
IFNγ prodiction  by  T  and  NK  cells.  This same IFNγ production is also thought to be responsible 
for the hepatotoxicity of IL-12. Using a constant, low dose gene-therapy approach to IL-12 
delivery, a novel mechanism that plays a key role in the anti-angiogenic properties of IL-12 was 
discovered (Morini M et al., 2004). Using gene targeted mice lacking IFNγ, IFNγ was found to not 
be requited for the anti-angiogenic activity (Morini M et al., 2004). Although initial gene targeted 
and antibody depletion approaches indicated both T and NK cells were not necessary (Morini M et 
al., 2004), later studies using dual targeted SCID/common gamma chain mice indicated that NK 
cells are critical for the anti-angiogenic activity of IL-12 (Faggioli F et al., 2008). Our unpublished 
data support this in other models where both T and NK cells are targeted, as well as those where 
NK cells alone are depleted. 
NK cells are delegated the “missing self” defense mechanism as they are endowed with the 
capacity to kill host cells that lack expression of MHC class I molecules. Peripheral NK cells are 
predominantly CD56dimCD16+ cytotoxic NK cells (90-95%). There is a minor constituent of 
peripheral NK cells that are CD56brightCD16- NK (5-10%) and associated with cytokine production. 
It is now well established that NK cells are a predominant cell type within the developing deciduas 
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during implantation. These decidual NK cells, or dNK, are also a cytokine producing and highly 
angiogenic phenotype relatively similar between humans and murine models (Hanna J. et al.,2006). 
These dNK cells are CD56superbrightCD16-, produce VEGF, PlGF and IL-8, and have been shown to 
significantly enhance growth of transplanted tumors by their angiogenic activity. Our hypothesis 
was that an NK subset similar to the dNK subset, could be present in tumors, potentially favoring 
tumor angiogenesis. Consistent with this concept, it has recently been shown that the stroma of 
human NSCLC tumors are infiltrated largely by CD56brightCD16- NK cells  (Carega P. et al., 2008) 
which appear to be selectively recruited into these tissues. Unlike the CD56brightCD16- NK subset 
found in peripheral blood, the tumor infiltrating cells express KIR receptors and appear to be 
indolent with reduced killing capacity but intact cytokine production. It is not known if these tumor 
infiltrating NK cells express VEGF, PlGF or IL-18, nor whether their phenotype can be switched to 
cytotoxic phenotype by IL-12. Importantly, there is increasing evidence that DC-NK cross-talk is a 
key regulator of the immune system, and our preliminary data indicate that their interaction also 
significantly influences the angiogenic phenotype.  
 
The goal of this project is to investigate the role of these cells in tumor angiogenesis in 
model systems as well as in human tumors. The data on the cellular and molecular mechanisms 
produced by this project will allow identification of key points that could well lead to development 
of new pharmaceutical targets for cancer therapy and consequent improvement of both patient 
survival and quality of life. 
 
This study was designed in order to evaluate: 
 
1. the role of NK cells in tumor angiogenesis by analyzing infiltrating cells in tumors derived 
from patients with non small cell lung cancer (NSCLC); 
2. to confirm the presence of a predominant phenotype in NK cells infiltrating tumors and 
compare this phenotype with non tumor NK cells;  
3. analyse cytokines production profiles of tumor infiltrating NK cells and clarify their role in 
tumor angiogenesis, according to the  phenotype displayed; 
4. the possible correlation between tumor infiltrating NKs phenotype/functionality also in 
relation with tumor histology and patiets smoking habits; 
5. identify new targets for anti-angiogenic therapy. 
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3.  MATERIALS  AND METHODS 
 
3. 1  Samples and patients selection 
 
Samples (tumor tissue and “normal” adjacent tissues recovered from the margins of the 
surgically resected material) were obtained from patients with NSCLC during surgical resections 
after obtaining informed consent. The tissue samples were placed in PBS with 1% Pen/Sstrep at 
4°C for no more than 18 hours prior to processing. Peripheral blood samples were drawn on the 
same patients prior to surgical intervention, stored at 4°C and processed within 18 hours. Patients 
with diabetes, HIV/HCV/HBV infection, other chronic inflammatory conditions, previously treated 
with chemotherapy or radiotherapy, or those iatrogenically immunosuppressed or having undergone 
myeloablative therapies were excluded. 
 
3. 2  Peripheral blood mononuclear cells (PBMCs) isolation 
 
In order to obtain mononuclear cells, a ficoll histopaque gradient was performed on 
peripheral blood by diluting the blood sample 1:1 with RPMI 1640 (LONZA). This suspension was 
then carefully stratified on Ficoll (LONZA) and centrifuged at 500 x g for 30 min. at room 
temperature with no brake. The lymphocyte containing ring at the interface was collected in a new 
tube and washed twice in PBS by centrifugation. 
 
3. 3  Solid tissue enzymatic digestion 
 
The solid tissues (tumor and adjacent normal tissues) were mechanically minced by scissors 
to obtain small fragments. The fragments were then digested with an enzymatic cocktail containing 
DNAse (100 µg/ml, Roche), Collagenase (1 mg/mL, Sigma Aldrich) in RPMI 1640 with 1% 
penstrep for 1 hour at 37°C. The suspension was then filtered on 50 µm pores cell strainers (BD) to 
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3. 4   Phenotypic characterization of tumor infiltrating NK cells 
 
Total NK cells obtained as previously described were assessed for subset distribution by 
Flow Cytometry. 3x105 cells per sample (blood, normal adjacent tissue, tumor tissue) were stained 
with anti human CD45-FITC, and CD16-FITC, CD3-PerCP and CD56-APC (BD). Briefly, after 
setting physical parameters (SSC, FSC), lymphocyte populations were individuated by gating on 
CD45 positive cells, then NK cells population was distinguished by subgating on CD3 negative 
cells and CD56 positive cells. CD3-CD56+ population was then evaluated for CD16+/- in order to 
characterize the distribution of these two NK subsets in blood, adjacent normal tissue and tumor. 
 
3. 5  Intracellular staining for cytokines profile analyses 
 
Total NK cells from blood and tissues were incubated overnight in RPMI 1640 added of 5% 
FCS, 1% Pen/Strep, IL-2 100 U/ml at 37°C, 5% CO2. Cells (5x105/ml) were then stimulated for 6 
hours with phorbol 12-myristate 13-acetate (PMA, 10 ng/ml), Ionomycin (Iono, 500 ng/ml) and 
Brefeldin-A (Golgi Stop, BD). The cells were then treated with Cytofix/Cytoperm fixation and 
permeabilization solution (BD). The expression of specific cytokines and angiogenic growth factors 
were then evaluated by flow cytometric analyses after staining with anti human CD45-FITC, and  
CD16-FITC, CD3-PerCP, CD56-APC combined with different PE-labeled anti-human cytokines 
antibodies (VEGF, IL-8, Angiopoietin-1, IFNγ).  
3x105cells per facs tube were stained for 30 min. with anti-human CD3-PerCP (Biolegend), 
CD56-APC (BD), CD16-FITC (BD), washed in PBS, then permeabilized with saponin (BD-
cytofix/citoperm kit) and stained with VEGF-PE (R&D), IL-8 (R&D), PlGF–PE (ABCAM), Ang-
1-PE (ABCAM). Excess of Abs was washed with PBS 1x at 500 x g, 4°C for 8 minutes. After 2 
washes, cells were resuspended in 500 µL of PBS + 0.5% BSA for citofluorimetric analyses (BD-
FACS Canto I). 
	  
3. 6  Immunohistochemistry of tumor samples 
 
A portion of each tumor sample was retained fixed in formalin and embedded in paraffin for 
routine histopathology.  Additional serial sections were stained with CD57 (indicative of activated 
NK cells), CD56 and CD3. Sections showing CD3-CD56+ cells were considered to be NK cells.  
The percentage of NK cells observed in the tissue samples was low and consistent the frequencies 
observed in flow cytometry 
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3. 7  NK cells enrichment for chemotaxis and morphogenesis assay 
	  
Total NKs, derived from blood and tissues samples were enriched by immunosorting with 
the MagCellect NK cell negative selection kit (R&D) from the cell suspensions obtained from 
blood, tumor and adjacent normal tissues. Briefly, cells were resuspendend into R&D MagCellect 
Buffer, then negative selection was performed by incubation for 15 min. with MagCellect Human 
NK Cell Biotinylated antibody Cocktail and 15 min. with MagCellect Streptoavidin Ferrofluidin 
reagent. Purity was greater than 80 % as determined by flow cytometry. 
 
3. 8  Chemotaxis and morphogenesis assay of lung tumor infiltrating NKs on Endothelial cells 
(HUVECs) 
 
NK cells purified from blood and tissues were incubated overnight as above. Cells (50x103 
cells/ml) were then incubated in RPMI 1640 with 1% Pen/Strep and were either stimulated for 6 
hours with phorbol 12-myristate 13-acetate (PMA, 10 ng/ml) and Ionomycin (Iono, 500 ng/ml) or 
untreated in the same culture medium. The cells were then removed by centrifugation and the 
supernatants recovered, filtered twice by 50 µm pore size filters to remove residual cells and debris, 
then concentrated with Concentricons (Millipore) devices with 5 kDa pore membranes, followed by 
reconstitution in PBS and re-concentration twice in order to remove residual PMA and Iono. The 
samples were then concentrated 10 fold and frozen at -20°C until use, and the samples were diluted 
to 1x when used.   
In order to evaluate the capacity of tumor infiltrating NKs to induce angiogenesis associated 
activities, we performed endothelial cell chemotaxis and morphogenesis assays in vitro. Since 
angiogenic factors induce endothelial cell migration and invasion in vitro, we evaluated the ability 
of NK cell products to induce chemotaxis of human umbilical vein endothelial cells (HUVECs, 
Promocell) in the Boyden chamber migration assay.  HUVECs were seeded (5x104 cells/well) in the 
upper compartment of a modified Boyden chamber; the lower compartment was filled with Cell 
culture supernatants derived from purified mitogen-stimulated or unstimulated NKs cells as 
described above. As a positive control M199 endothelial growth medium (Sigma, St Louis, MO, 
USA), supplemented with 10% heat-inactivated FBS, 1% glutamine, fibroblast growth factors (1 µg 
acid-fibroblast growth factor plus 1 µg basic-fibroblast growth factor /100 ml), epidermal growth 
factor (1 µg/100 ml), heparin (10 mg/100 ml) and hydrocortisone (0.1 mg/100 ml) was used. After 
incubation (6 hours, 37°C, 5% CO2) filters were collected and cells were fixes and stained with 
DAPI, filter attached migrated cells were then counted. 
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Angiogenic stimuli also induce the formation of capillary-like networks by endothelial cells 
seeded on matrigel in vitro. For these morphogenesis assays, a 24-well plate, pre-chilled at -20°C, 
was carefully filled with 300 µl/well of liquid Matrigel (10 mg/ml) avoiding bubbles with a pre-
chilled pipette, and allowed to polymerize for 1 h at 37°C. HUVECs (5x104 cells/well) were plated 
after resuspension in 1 ml of tumor infiltrating stimulated (PMA/Iono) or unstimulated NK cell 
supernatants as described above. The effects on the growth and morphogenesis of endothelial cells 
were recorded after 6 and 24 h with an inverted microscope (Leitz DM-IRB) equipped with CCD 
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4.  RESULTS 
 
4. 1  Patient Characteristics 
 
	   NK cells were isolated from 31 lung cancer patients undergoing tumor resection (median 
age was 71, range: 44-79), as well as 10 patients undergoing resection for pneumothorax, (median 
age 27, range 16-69), whose characteristics are shown in Tables 1 and 2. Consistent with the 
population at risk, the majority of the cancer patients were males (90%) and either former or current 
smokers (90%). The most frequent histologic type was adenocarcinoma (55%), followed by 
squamous cell carcinoma (29%), and tumors of other histologic subtypes. The controls (Table 1) 
were notably younger in age, predominantly male (90%) and current or former smokers (70%). As 
previously observed (Carega P. et al., 2008), NK cells represent approximately 5% of the total 
CD45+ cells within tumors, adjacent lung tissues and in the peripheral blood (Table 2). 
 
4. 2  The CD56brightCD16- NK cells subset predominates in NSCLC tumor infiltrating NK cells 
as compared to control lung tissue compartments 
 
NKs can infiltrate solid tumors, displaying different phenotypes that correlate with 
functional activity in terms of cytokine production and cytotoxicity, and potentially inhibiting or 
promoting tumor angiogenesis.  Previous studies have shown that tumor samples from patients with 
NSCLC are enriched in the CD56+CD16- NK subset (Carrega P. et al., 2008). These CD56+CD16- 
tumor infiltrating cells have a limited capacity to kill tumor cells through an IFNγ and TNFα 
mediated mechanism. Here we confirm that the CD56+CD16- NK subset is predominant in lung 
tumor samples (Fig. 1A) with respect to the related peripheral blood and normal adjacent lung 
tissue. The average level of these cells is significantly higher (P<0.001) than that in the adjacent 
lung tissue and peripheral blood samples. Although the average age of the control population was 
significantly different from that of the cancer patient population, the lung tissues from non-
oncologic patients showed a predominant CD56dimCD16+ profile similar to that of the resected 
normal adjacent tissues lung tissues of oncologic patients (Fig. 1B).  We did not observe any 
significant differences regarding the predominance of the CD56+CD16- NK subset between 
histological subtypes: the CD56+CD16- NK subset predominated in adenocarcinomas and 
squamous cell carcinomas (Fig. 1C), as well as occasional mixed adeno-squamous or large cell 
carcinomas (data not shown).  Further, we did not observe any difference in distribution of NK cell 
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phenotype on the basis of smoking status, as samples from non-smokers, former smokers and 
current smokers showed essentially the same distribution in tumor and adjacent lung tissues (Fig. 
1D).  Smoking status also did not affect the distribution of the CD56+CD16- NK subset in control 
patients as well (data not shown).   
 
4. 3  The CD56brightCD16- NK subset is associated with production of angiogenic cytokines 
 
 The CD56+CD16- subset has been described as a potent producer of several cytokines 
(Cooper M. A. et al., 2001). Since dNKs have been reported to produce angiogenic factors (Hanna 
J. et al., 2006), we evaluated the capacity of the CD56+CD16- NK subset, predominant in NSCLC 
tumors, to produce several angiogenic factors, in particular VEGF, PlGF, IL-8, and Angiopoietin-1 
(Ang-1). Further, production of IFNγ, a key immunomodulatory cytokine also endowed with anti-
angiogenic potential (Indraccolo S. et al., 2007) was investigated. The tumor CD56+CD16- NK cell 
subset was clearly associated with significantly higher production of pro-angiogenic factors (Fig. 
2), in particular VEGF, PlGF and IL-8. Interestingly, only peripheral blood CD56+CD16- NK cells 
significantly produced the anti-angiogenic cytokine IFNγ, which instead was produced at very low 
levels by the tissue and tumor infiltrating NK cells.  A similar profile was observed with production 
of Ang-1. These data suggest a possible role of the CD56+CD16- NK cell subset in tumor 
angiogenesis in NSCLC.   
 
4. 4  Squamous cell carcinomas show NK cells producing very high levels of angiogenic factors 
 
 We then examined the distribution of cytokine and angiogenic factor production as a 
function of histotype and clinical parameters.  The adenocarcinomas all showed a similar lower 
level of production of angiogenic growth factors with the CD56+CD16- subset producing VEGF and 
PlGF (Fig. 3). However, we noted that VEGF production by NK cells in patients with squamous 
cell carcinomas was significantly higher than in those with adenocarcinomas in tumor and adjacent 
lung tissue as well as in peripheral blood NK cells (Fig. 3). NK cells from patients with squamous 
cell carcinomas also produced significantly higher levels of PlGF than in those with 
adenocarcinomas in the adjacent lung tissue and peripheral blood compartments (Fig. 3). We then 
examined the correlation of the patients with high angiogenic cytokine production with that of 
histological and clinical parameters within the squamous carcinoma samples. Expression of CD56+ 
was limited to few cells showing characteristics of NK morphology in most of the NSCLC samples, 
with occasional staining of the tumor epithelial compartment. Most of the CD56+ cells with an NK 
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phenotype were CD3-, and the numbers of these cells correlated well with those identified by flow 
cytometry (Table 2).  The samples all showed highly vascularized tumors as determined by CD31 
staining (Fig. 4), although this was characteristic of most of the NSCLC samples. We did not find 
other clinical parameters within the squamous carcinoma patient group that overtly correlated with 
the high level of production of VEGF and PlGF by NK cells in the tumor, adjacent tissue or 
peripheral blood.  
 
4. 5  Tumor infiltrating NK CD56+CD16- functionally promotes angiogenesis by recruiting 
endothelial cells and inducing formation of capillary like networks 
 
 Angiogenesis is a necessary process for tumor growth, survival and metastasis. Immune 
cells can infiltrate solid tumors displaying different phenotypes that correlate with tumor 
angiogenesis. Here we confirmed that NSCLC tumor infiltrating NK cells are enriched in the 
CD56+CD16- subset, and demonstrate that this phenotype is associated with production of the 
angiogenic factors VEGF, PLGF, IL-8, and Angiopoietin-1. In order to evaluate the functional 
capacity of these cells to promote tumor angiogenesis, we examined the effects of NK cell products 
on in vitro biological correlates of angiogenesis, in particular endothelial cell recruitment and 
morphogenesis.  
Supernatants from stimulated NSCLC tumor infiltrating NK cells were able to induce 
HUVEC chemotaxis (Fig. 5), while that of unstimulated cells was significantly less, suggesting this 
effect was due to NK cells and not eventual contaminating tumor cells. The chemotaxis effect of 
supernatants from adenocarcinoma cells was more apparent than that from squamous carcinomas 
(Fig. 5).  
We then examined the ability of NK cell supernatants to promote capillary-like remodeling 
of HUVE cells seeded onto matrigel 3D support. Supernatants from NSCLC adenocarcinoma 
infiltrating NK cells stimulated by PMA and Iono induced endothelial cell morphogenesis in vitro 
following stimulation (Fig. 6).  Interestingly, in this assay the unstimulated NK cells derived from 
squamous cell carcinomas showed a baseline angiogenic activity that was greatly enhanced 
following stimulation (Fig. 6). Network formation in the presence of supernatants of NK cells 
isolated from control non-oncologic tissue and peripheral blood NK cells was very limited (fig 6).   
Taken together, these data suggest that NK cells infiltrating into NSCLC tumors have an enhanced 
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5.  DISCUSSION 
	  
 
 Squamous cell carcinomas show some distinguishing characteristics as compared to 
adenocarcinomas, including their response to anti-angiogenic therapy.  Previous studies have shown 
that surgically resectable samples of squamous cell carcinomas have significantly more rapid 
doubling times (25% less) that those of surgically resectable adenocarcinomas (Arai T. et al., 1994).  
In the same case series, the faster doubling time was clearly a prognostic factor (Arai T. et al., 
1994), thus in this series the squamous cell carcinomas were on the average more aggressive 
clinically.  
Our data shows that the CD56+CD16- NK cell subset expresses proangiogenic cytokines that 
could contribute to tumor angiogenesis in NSCLC. The levels of these cytokines were particularly 
high in CD56+ CD16- NK cells of patients with squamous cell carcinoma, both tumor infiltrating 
but to an even greater extent in tissue and peripheral blood NK cells. These observations indicate 
that squamous NSCLCs have a potent influence on NK cells, exerting alterations in the phenotype 
of these cells both locally and systemically. The presence of a squamous cell carcinoma, even of 
modest dimensions, appears to have a potent effect on the phenotype of the CD56+CD16- NK cells 
at a systemic level.  In patients with squamous cell carcinomas, significantly higher levels of 
production of VEGF, a principal ligand of VEGFR1 and VEGFR2, by CD56+CD16- NK cells is 
found in both tumor tissue, adjacent lung tissue and in circulating peripheral blood. Further, in 
patients with squamous cell carcinomas we observed significantly higher levels of PlGF production, 
a specific VEGFR1 agonist, by CD56+CD16- NK cells only in the adjacent lung tissue and in 
circulating peripheral blood. The levels of cytokine production in peripheral blood CD56+CD16- 
NK cells dropped to baseline levels following surgical intervention in subsequently disease-free 
patients. These data indicate that these cells could have a diagnostic, prognostic or monitoring 
significance in squamous NSCLC.  
We note that several studies have found lower vessel densities in normal tissues as 
compared to tumor tissues, in particular lung (Eberhard A. et al., 2000; Regina S. et al., 2008). Two 
studies reported lower microvessel density (MVD) in squamous cell carcinomas as compared to 
adenocarcinoms (Ozbudak I. et al., 2009), while another article observed a similar trend in 
surgically resected NSCLC that, however, was not statistically significant (Imoto H. et al, 1998). 
Interestingly, VEGF staining was found to be an independent prognostic indicator of survival for 
resectable lung cancer patients, particularly for those of the squamous histotype (Imoto H. et al, 
1998). A subsequent study, however, found no difference in the production of VEGF165 between 
tumor and adjacent lung tissues, while VEGF189 was found to be lower in the tumor tissues 
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(Regina S. et al, 2008). We sought to correlate the production of pro-angiogenic cytokines by NK 
cells with the MVD in the squamous cell carcinomas studied here, however no clear correlations 
were found. The high systemic production of these cytokines could produce a reduction in local 
vessel density, as circulating VEGF could “compete” for local VEGF, reducing the gradient effect 
and effectively lowering angiogenesis. Further, the high levels of systemic VEGF and PlGF are 
likely to enhance vessel permeability. 
Bevacizumab has now entered into clinical use for NSCLC adenocarcinomas as an anti-
angiogenic agent in combination chemotherapy. In contrast, it is not used for squamous cell 
carcinomas as these patients showed a tendency for life-threatening hemorrhages (Reck et al., 2009) 
Thus, identification of groups that may respond well to anti-angiogenic agents or those likely or not 
to have hemorrhages would permit entry of these drugs into the squamous NSCLC subset as 
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Table 2: percentage of CD3-CD56+CD16- tumor infiltrating NKs over total NKs (CD45+CD3-CD56+ cells) in 
comparison with blood and adjacent normal tssues from patients with NSCLC. CD3-CD56+CD16- NKs subset 
represents the predominalt part of tumor infiltrating cells both in tumor histotypes (ADK and SQK) and  
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Figure 1. Phenotypic distribution of the CD3-/CD56+/CD16+ and CD3-/CD56+/CD16- NK cell subsets as 
determined by flow cytometry.  (A) NK cell distribution in samples derived from peripheral blood, normal 
adjacent lung tissues and tumor tissues of patients with NSCLC (B) A similar distribution of NK cell subsets is 
found in peripheral blood and lung tissues from non-oncologic patients. (C) The tumor infiltrating NK cells are 
primarily of the CD3-/CD56+/CD16- subset in both adenocarcinomas and squamous cell carcinomas. (D) 
Smoking status does not influence the NK cell subset in tumor or adjacent lung tissues. 
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Figure 2. Characterization of tumor infiltrating NK cells by intracellular staining for angiogenic and anti-
angiogenic cytokines.  The CD3-CD56+CD16- NK cell subset is clearly associated with enhanced cytokine 
production, including VEGF, PlGF and IL-8 in the tumor and adjacent normal tissues as well as peripheral 
blood.  In the peripheral blood, the CD3-CD56+CD16- NK cell subset was also associated with enhanced 
production of Angiopoietin 1 and IFNγ . 
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Figure 3: CD3-CD56+CD16- NK cells from patients with squamous cell carcinomas produce significantly more 
VEGF than those from patients with adenocarcinomas.  This was appaerent both locally in the tumor but also 
systemically in the adjacent tissue and in the peripheral blood. In addition, CD3-CD56+CD16- NK cells from 
peripheral blood and adjacent tissue from patients with squamous cell carcinomas produced significantly more 
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Figure 4. Immuno-histochemistry of squamous cell carcinomas. (A) CD56 staining of squamous cell carcinoms 
show occasional positive cells scattered throughout the tumor.  (B) CD31 staining shows extensive 




Figure 5. Analysis of the capacity of supernatants from NK cells derived from adenocarcinomas or squamous 
cell carcinomas to induce endothelial cell chemotaxis. SFM-: serum free medium as a negative control, 
containing M199 endothelial growth medium alone.  SFM+: serum free M199 endothelial growth medium 
(Sigma, St Louis, MO, USA), 1% -glutamine, fibroblast growth factors (1µg acid-fibroblast growth factor plus 
1µg basic-fibroblast growth factor /100ml), epidermal growth factor (1µg/100ml), heparin (10mg/100ml) and 
hydrocortisone (0.1mg/100ml). CM: complete medium containing SFM+ medium supplemented with 10% heat-
inactivated FBS serum as a positive control.  Supernatants from NK cells isolated from adenocarcinomas (AdK) 
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and squamous cell carcinomas (SqK) that were stimulated for 6 hours with PMA and Iono (S) showed enhanced 
induction of chemotaxis as compared to supernatants from NK cells that were untreated in the same culture 




Figure 6. Analysis of the capacity of supernatants from NK cells derived from adenocarcinomas or squamous 
cell carcinomas to induce endothelial cell morphogenesis. SFM-: serum free medium as a negative control 
containing M199 endothelial growth medium alone.  SFM+: serum free medium containing serum free M199 
endothelial growth medium (Sigma, St Louis, MO, USA), 1% -glutamine, fibroblast growth factors (1µg acid-
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fibroblast growth factor plus 1µg basic-fibroblast growth factor /100ml), epidermal growth factor (1µg/100ml), 
heparin (10mg/100ml) and hydrocortisone (0.1mg/100ml). CM: complete medium containing SFM+ medium 
supplemented with 10% heat-inactivated FBS serum as a positive control. Supernatants from NK cells isolated 
from adenocarcinomas (AdK) that were stimulated for 6 hours with PMA/Iono (S) showed induction of 
morphogenesis as compared to supernatants from unstimulated (NS) NK cells. Supernatants from NK cells 
isolated from squamous cell carcinomas (SqK) showed induction of morphogenesis even when unstimulated 
(NS).  The induction of morphogenesis by these cells was further enhanced upon stmulation (S), indicating that 
these cells harbor a strong angiogenic activity.  NK cells isolated from the peripheral blood (blood) or lung 
tissues (tissue) of non oncologic patients did not show significant enhancement of morphogenesis in the presence 
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